Cardiopulmonary disease is the leading cause of mortality in adults with sickle cell disease (SCD). Elevated tricuspid regurgitant jet velocity (TRJV) and reduced forced expiratory volume in 1 second (FEV 1 ) %predicted are associated with early mortality in SCD; however their relationship and combined effect on survival is unknown. We investigated the relationship between TRJV and FEV 1 %predicted, and their combined effect on mortality, in a retrospective cohort of 189 adults with SCD who underwent both pulmonary function testing and echocardiography. Nineteen (9.9%) of 189 patients died over a median follow-up of 1.4 years; cardiopulmonary disease was the major cause of death in 52.6%. FEV 1 %predicted was negatively associated with TRJV (Spearman rho, 20.34, P < 0.001). Individuals with FEV 1 %predicted 70% were more likely to have an elevated TRJV 2.5 m/second, compared to those with FEV 1 %predicted >70% [45.8% versus 17.1%; odds ratio (OR) 4.1 (95% Confidence interval ([CI] 2.1-8.0); P 5 0.001]. In a multivariable cox regression model, the combination of TRJV 2.5 m/second and FEV 1 %predicted 70% predicted earlier mortality [hazard ratio (HR) 4.97 (95% CI 1.30-18.91; P 5 0.019)] after adjusting for age, sex, and nephropathy. Both FEV 1 %predicted 70% and TRJV 2.5 m/second were independently associated with nephropathy [OR 4.48 (95% CI 1.51-13.31); P 5 0.004] and [OR 3.27 (95% CI 1.19-9.00); P 5 0.017], respectively. In conclusion, pulmonary and cardiac impairment are associated with, and contribute to mortality in SCD. Therapies aimed at improving reduced FEV 1 %predicted and elevated TRJV could improve survival in patients with SCD.
Introduction
Cardiopulmonary disease is the leading cause of mortality in sickle cell disease (SCD) [1] [2] [3] [4] . While acute chest syndrome (ACS) accounted for the majority of deaths in past decades, 2 recent data indicate that adults with SCD are predisposed to chronic cardiopulmonary disease, which accounts for 20-40% of deaths [2, 5, 6] . Elevated tricuspid regurgitant jet velocity (TRJV), a predictor of pulmonary hypertension, has been reported in 20-40% of adults with SCD [6] [7] [8] with an associated mortality rate as high as 21.4% over 62.5 months [9] . Recently, asthma and recurrent wheezing have been associated with increased SCD-related morbidity (vaso-occlusive pain and ACS) and earlier death [10] [11] [12] [13] . Further, an analysis from the Cooperative Study for Sickle Cell Disease (CSSCD) demonstrated that low forced expiratory volume in 1 second (FEV 1 ) %predicted is an independent predictor of earlier death in adults with sickle cell anemia (SCA); the presence of obstructive or restrictive lung disease were not associated with earlier death [14] . However, this study was limited because there was no measurement of TRJV, a potential confounder for earlier death. Similarly, none of the large prospective cohort studies demonstrating a relationship between elevated TRJV and earlier death included any assessment of FEV 1 %predicted. Using a retrospective cohort study design, we tested the hypothesis that both cardiopulmonary risk factors for death, elevated TRJV measurement and a reduced FEV 1 %predicted value would have a higher hazard ratio of death in adults with SCD than with either risk factor alone. We also evaluated the relationship between elevated TRJV measurement, a surrogate for pulmonary hypertension, and reduced FEV 1 % predicted, which has not been evaluated in prior studies.
Study Design

Patients and data collection
The institutional review board at Vanderbilt University Medical Center approved this study. This retrospective cohort study was designed to include adults with SCD, documented by high-performance liquid chromatography, who were followed at the Vanderbilt-Meharry Center for Excellence in SCD from January 1, 2003 to January 31, 2016 , at which point data were censored. Our institutional practice is to perform annual pulmonary function testing and echocardiography in all patients with SCD. Overall compliance with this practice is 74.7%. Only individuals with SCD 18 years of age who had undergone both pulmonary function testing and echocardiography were included. A priori, we determined the most recent set of spirometry results and echocardiographic data performed in the outpatient setting, when the individual is not acutely ill or hospitalized, and within 1 year of each other, were collected as the index measurements. For spirometry results, percent predicted values were determined for each individual based on their age, sex, height, and race for FEV 1 , forced vital capacity (FVC), and the ratio of FEV 1 /FVC, calculated using the Global Lung Initiative 2012 equations [15] . We prospectively categorized FEV 1 % predicted values as 70% or >70% because this threshold has been associated with a higher rate of mortality in adults with SCA [14] . Percent predicted values for total lung capacity (TLC) were obtained using the prediction equations published by Stocks and Quanjer [15] and adjusted by 12% to account for the effect of race on these values [16] . We defined a TRJV measurement cutoff of 2.5 m/second as abnormally elevated and indicative of pulmonary hypertension based on the study by Gladwin and colleagues and supported by the American Thoracic Society clinical practice guideline on pulmonary hypertension in SCD [6, 17] . Individuals with trace or no tricuspid regurgitation were classified not having an elevated TRJV measurement (n 5 55). Potential covariates associated with earlier death were also evaluated; these included the frequency of pain episodes, ACS, nephropathy (defined as a serum creatinine of 2 mg/dl or 1.5 times the baseline creatinine or an estimated glomerular filtration rate of <60 ml/min/1.73 m 2 body surface area persistent over at least 3 months based on the National Kidney Foundation Kidney Disease Outcomes Quality Initiative [NKF KDOQI] guidelines) [18] , stroke, disease-modifying therapy (hydroxyurea or chronic transfusion therapy), smoking status, and asthma diagnosis based on documentation in the medical records. Baseline (not during an encounter for vaso-occlusive pain or ACS) laboratory studies including hematocrit, platelet count, reticulocyte count, renal function, and serum lactate dehydrogenase were also collected. Date and cause of death were collected from the medical record, when available. Survival time was computed from date of echocardiographic assessment to last clinical encounter or death.
Analysis plan
Data were summarized as counts and percentages, and means with standard deviations (or medians and interquartile range [IQR] ). Differences by survival status were tested for categorical covariates with a chisquare test. Continuous covariates were tested with the Student's t-test or the Wilcoxon Mann-Whitney U test for normal and non-normal distributions, respectively. We assessed associations between FEV 1 % predicted and TRJV measurement (treated as continuous variables) using the Spearman correlation test. Additionally, we evaluated the association between reduced FEV 1 %predicted value (70%) and elevated TRJV measurement 2.5 m/second measurement with the presence of nephropathy using a chi-squared test. Patients were categorized into the following groups: (1) TRJV <2.5 m/second and FEV 1 % predicted >70%; (2) TRJV <2.5 m/second and FEV 1 % predicted 70%; (3) TRJV 2.5 m/second and FEV 1 % predicted >70%; (4) TRJV 2.5 m/second and FEV 1 % predicted 70%.
To identify associations with mortality, a baseline multivariable Cox regression model was constructed. The effect of TRJV and FEV 1 % predicted was adjusted for known predictors of mortality including age, sex, and renal disease [18] . The model was limited to only these three covariates because of the small proportion of deaths (10%: 19 of 189). We used the categorized combination variable of TRJV measurement (2.5 m/second and <2.5 m/second) and FEV 1 %predicted value (>70% predicted and 70% predicted) in the models. After the final model was constructed, serum lactate dehydrogenase, reticulocyte count, asthma, and smoking status were added, one at a time, to determine whether they added significantly to predicting survival. The proportional hazards assumption was assessed, and Martingale and deviance residuals were used to assess model assumptions and the effect of outlier cases. In order to examine the independent effects of TRJV measurement 2.5 m/second and FEV 1 % predicted value of 70% on mortality, we also evaluated a model in which these covariates were included as separate variables along with age, sex, and nephropathy. A P-value of <0.05 was considered significant for all analyses. SPSS version 23 (IBM Corp, USA) was used to perform all analyses.
Results
Participant characteristics
From a pool of 254 adults with SCD followed at Vanderbilt-Meharry center for Excellence in SCD, we identified 189 individuals with SCD who had undergone both pulmonary function testing and echocardiogram within a 12-month period of each other. To assess selection bias for pulmonary function testing and echocardiogram assessment, we compared individuals who underwent pulmonary function testing and echocardiography (N 5 189; included in analysis) and those who did not (N 5 64; excluded from analysis). There were no significant differences between these two groups, Supporting Information Table S1 . The baseline characteristics of the study population are summarized in Table I . Asthma was present in 15.1% and 19.0% were smokers at the time of evaluation. FEV 1 % predicted value 70% was present in 38.1%, and 28.0% had elevated TRJV measurement of 2. TRJV 2.5 m/second and FEV 1 % predicted 70%, in combination, predict early mortality A composite variable of TRJV and FEV 1 % predicted was a significant predicator of mortality. The combination of TRJV measurement 2.5 m/second and FEV 1 % predicted value 70% was strongly associated with higher mortality with a hazard ratio (HR) of 4.97 (95% CI 1.30-18.91; P 5 0.019). The other combinations of TRJV and FEV 1 % predicted had HR similar to those reported in previous studies, but not statistically significant, with FEV 1 % predicted value >70% and TRJV measurement 2.5 m/second having a HR of 3.78 (95% CI 0.79-17.61; P 5 0.094), and FEV 1 % predicted 70% and TRJV <2.5 m/second having a HR of 1.09 (95% CI 0.22-5.15; P 5 0.915), Table II and Supporting Information Figure S1 . The other postulated covariates in the primary model (age, sex, and nephropathy) were not independently associated with increased hazard of death; although the HRs for sex and nephropathy were relatively high at 2.78 for both. When elevated TRJV measurement and reduced FEV 1 % predicted values, as separate categorical values, were put in the model with age, sex and nephropathy, the HRs were 4.20 (95% CI 1.50-11.75; P 5 0.006) and 1.21 (95% CI 0.41-3.57; P 5 0.734), respectively. The effect of the combination of TRJV and FEV 1 % predicted is reflected in the overall mortality rates for the 4 groups. Over the follow up period, deaths occurred in 4.1% of those with TRJV <2.5 m/sec and FEV 1 %predicted >70% (mortality rate 1.52 per 100 patient-years (4/263), 7.7% of those with TRJV <2.5 m/sec and FEV 1 %predicted (mortality rate 3.49 per 100 patient-years (3/86), 15.0% of those with TRJV 2.5 m/sec and FEV 1 %predicted >70% (mortality rate 11.04 per 100 patient-years, 3/27), and 27.3% of those with TRJV 2.5 m/sec and FEV 1 %predicted 70% (mortality rate 19.07 per 100 patient-years (9/47).
The small sample size with only 19 deaths precludes extensive multivariable analysis; therefore, each additional postulated risk factor for death was added to the base model one at a time, and none were associated with earlier death, including serum lactate dehydrogenase level (HR 1.00; P 5 0.935), reticulocyte count (HR 0.01; P 5 0.084), presence of asthma (HR 2.20; P 5 0.271), and smoking (HR 2.00; P 5 0.183).
Cardiopulmonary disease is the most common cause of death
Approximately 10% (19 of 189) of the retrospective cohort died during the follow-up period. The primary and secondary causes of death were identified for 89.5% (17 of 19) of the adults in the cohort, Table III . Cardiopulmonary disease was the primary cause of death in 52.6% of patients, followed by neurologic complications in 21.0%, and end stage renal disease in 10.5%. Among the individuals who died, the largest proportion (47.4%; 9 of 19) had the combination of both FEV 1 % predicted measurement 70% and TRJV value 2.5 m/ second. A further 26.3% (5 of 19) of the individuals who died had FEV 1 % predicted measurement >70% and TRJV value 2.5 m/second, 15.8% of the individuals who died (3 of 19) had FEV 1 % predicted measurement 70% and TRJV value <2.5 m/second, and only 10.5% of the individuals who died (2 of 19) had FEV 1 %predicted measurement of >70% and TRJV value <2.5 m/second.
Discussion
Cardiopulmonary complications are the most common cause of death in adults with SCD; however, the associations between the two, and the relative contribution of lung disease, cardiac complications, or both have not been well-documented. We have demonstrated for the first time an association between elevated TRJV values and reduced FEV 1 % predicted measurements in adults with SCD, supporting a link between pulmonary and cardiac disease in SCD. A combination of TRJV value 2.5 m/second and FEV 1 % predicted measurement of 70% are risk factors for earlier death. When evaluated separately, elevated TRJV values remained a predictor for mortality and reduced FEV 1 % predicted <70% was not a predictor of mortality. Reduced FEV 1 % predicted is a risk factor in the general population [19] [20] [21] as well as adults with other pulmonary diseases such as cystic fibrosis [22] . The lack of association of reduced FEV 1 % predicted with mortality in the present study may be attributable, in part, to the small number of deaths in the sample. Our findings highlight the need to further elucidate the relationship between lung and cardiac disease in SCD.
We previously postulated that progressive vasculopathy leading to end-organ damage in SCD was unlikely to be isolated to one organ, but affected multiple organs simultaneously [23] . For the first time in adults with SCD, we have simultaneously included assessments of impairment of three end organs (heart, lung and kidney) to identify whether the presence of both cardiac and pulmonary disease is a combined risk factor for death. In addition to a relationship between impaired pulmonary function and elevated TRJV, a proxy for pulmonary hypertension, our findings also highlight an association of reduced FEV 1 %predicted and elevated TRJV measurement with the presence of nephropathy. These data coincide with studies demonstrating at least an association between elevated TRJV measurement and renal disease, including albuminuria, in patients with SCD [9, 24, 25] . The relationship between hemolysis, pulmonary impairment, renal and cardiac disease in SCD is poorly understood; however it is likely that there are common underlying pathologic mechanisms [23] . A comprehensive prospective study is necessary to assess the timing and development of end-organ dysfunction in this patient population and to determine the sequence of organ involvement and relative contribution of affected organs to earlier mortality in adult patients with SCD. Based on the strong correlation between end-organ disease in different organs, future clinical studies isolated to either treatment or assessment one end-organ disease (renal, lung or heart) are likely to underestimate the true disease burden of the individual.
As anticipated, in this study, cardiopulmonary disease was the leading cause of death, as well as catastrophic cerebral infarcts or hemorrhage and progressive renal disease. Our cohort was established during the era of disease-modifying therapy and thus provides information pertinent to the contemporary care of adult patients with SCD. The relationship between elevated TRJV measurements and mortality in adults with SCD was first shown by Gladwin et al. and has been validated by multiple prospective studies [6, 8, 9, [26] [27] [28] . In our analysis, the combination of elevated TRJV measurement and reduced FEV% predicted measurement, adjusted for nephropathy and age, was associated with earlier mortality. An important difference between our study and previous reports is that none of the previous studies demonstrating associations between TRJV measurements and earlier death simultaneously adjusted for abnormal pulmonary function or impaired renal function. In particular, the initial study that identified TRJV measurement 2.5 m/second as a predictor of mortality in SCD also reported that a self-reported history of renal disease was associated with elevated TRJV measurement 2.5 m/second; however, the predictive model for mortality was adjusted for creatinine level, but not for a persistent increase from baseline serum creatinine level [6] . Serum creatinine at any one point in time is a poor measure of glomerulopathy in individuals with SCD because of hyperfiltration [29, 30] and increase in tubular excretion of creatinine [31] . To define active kidney disease, we used the more robust definition of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative which includes an estimated glomerular filtration rate of <60 ml/min/1.73 m 2 body surface area or serum creatinine elevated 1.5 times above the baseline, persistent over at least 3 months. In addition to including impairment of the three potentially involved organ systems (kidney, lung, heart) in the multivariable model to address their relative contribution to earlier mortality, we have provided concomitant data about primary and secondary causes of death, which was not reported in previous studies. As expected, based on the multivariable analysis, cardiopulmonary disease was the most common primary or secondary cause of death (Table III) . Although nephropathy and asthma were not statistically associated with earlier death, the magnitude and direction of hazard ratios are similar to prior reports [1, 12] . To better understand the complete spectrum of risk factors for earlier deaths in SCD, a prospective multicenter cohort study will be necessary.
This retrospective cohort study has some limitations. As this was a cross-sectional analysis of pulmonary function and echocardiographic data, we were unable to assess the progression or onset of end-organ disease. Also, a single assessment of pulmonary function is not an optimal strategy to ensure accurate classification of patterns of pulmonary function abnormalities. Although the inclusion of variables such as N-terminal pro-brain natriuretic peptide, which has been associated with pulmonary hypertension and earlier mortality [32, 33] , and microalbuminuria would have been of interest, these would not have altered our classification of progressive endorgan disease, and had they been available, would have been complimentary to our end organ assessment Finally, this was a single-center study with only 19 deaths. Our results will need to be prospectively validated in a large multicenter cohort study that includes longitudinal assessment of pulmonary and cardiac function along with markers of hemolysis.
We demonstrate that reduced FEV 1 % predicted measurements are associated with elevated TRJV values. Furthermore, after adjusting for the presence of renal disease, we provide preliminary evidence that the presence of both FEV 1 % predicted measurement 70% and TRJV values 2.5 m/second are strong predictors of earlier death in adults with SCD. Our findings highlight the need to further elucidate the relationship of renal, pulmonary and cardiac disease in SCD, coupled with the urgent need to develop SCD-specific targeted therapies to improve TRJV and FEV 1 %predicted in adults with SCD.
